Silo Pharma Looks to Become a NASDAQ Biotech
October 4th, 2021
Psychedelics, Top Story
Silo Pharma Inc. (OTCQB: SILO) is a cutting-edge, development-stage biotechnology company focused on merging traditional therapeutics with emerging psychedelic research for people suffering from indicators such as depression, post-traumatic stress disorder, Parkinson’s disease, and other rare neurological disorders, representing billion-dollar markets.
The company submitted an initial application to list on the NASDAQ Capital Market—a move that could provide greater liquidity and attract institutional investors. The uplisting could also increase the stock’s price by making it easier for mainstream investors to purchase the stock in accounts prohibiting over-the-counter securities.
Let’s look at how the company is building a foundation for success with blue-sky potential ahead.
Building a Foundation
Silo Pharma recently disclosed the sale of 1,000,000 shares of DatChat Inc., a non-core asset, for aggregate proceeds of approximately $6.6 million. The move further improves the company’s robust balance sheet that consisted of more than $4 million in cash and just $1.2 million in total liabilities last quarter.
The company has ample cash on its balance sheet to continue its collaborations with the University of Maryland-Baltimore (UMB), University of California-San Francisco (UCSF), and Zylo Therapeutics. In addition, the company continues to build out its psychedelic patent portfolio that lays the groundwork for clinical trials ahead.
The company’s partnerships and IP portfolio serve to validate its patented drug delivery system that lies at the heart of its business. Unlike pharmaceutical companies that put all of their eggs in one basket, its management team aims to reduce risk through these validations and focus its efforts on licensing agreements.
Silo Pharma’s unique delivery technology could have a significant impact across many different medications and indications. In essence, the technology delivers traditional therapeutics, psilocybin, or other psychedelic drugs directly to targeted areas of the body to reduce toxicity and the amount of medication required.
The company’s initial research agreements and joint ventures focus on multi-billion dollar opportunities, such as Parkinson’s disease, bipolar disorder, chronic back pain, multiple sclerosis, and other conditions. Meanwhile, its collaboration with Zylo focuses on adding a transdermal delivery mechanism to improve efficacy further.
Finally, the company’s licensing-focused business model could pave the way for a combination of upfront licensing payments and ongoing royalties with minimal capital expenditures. As a result, investors could see recurring income that’s tied to the success of its patented drug delivery system without significant dilution over time.
Silo Pharma Inc. (OTCQB: SILO) provides investors with entry into the exciting psychedelics industry and the recent $6.6 million asset sale should accelerate their business model. With plans to list on the NASDAQ, the company could be nearing an inflection point with easier access to capital and a more extensive shareholder base.
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.